Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BI 770371
i
Other names:
BI 770371, BI-770371, BI770371
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Boehringer Ingelheim, OSE Immunotherapeutics
Drug class:
SIRPA antagonist
Related drugs:
‹
RRx-001 (2)
BMS-986351 (1)
ADU-1805 (0)
ALTA-002 (0)
BI 765063 (0)
DS-1103 (0)
IBC0966 (0)
LM-101 (0)
RRx-001 (2)
BMS-986351 (1)
ADU-1805 (0)
ALTA-002 (0)
BI 765063 (0)
DS-1103 (0)
IBC0966 (0)
LM-101 (0)
›
Associations
News
Trials
Filter by
Latest
10d
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH (clinicaltrials.gov)
P2, N=24, Not yet recruiting, Boehringer Ingelheim
10 days ago
New P2 trial
|
BI 770371
3ms
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
P1, N=13, Recruiting, Boehringer Ingelheim | Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
3 months ago
Trial completion date • Trial primary completion date • Metastases
|
SIRPA (Signal Regulatory Protein Alpha)
|
ezabenlimab (BI 754091) • BI 765063 • BI 770371
4ms
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (clinicaltrials.gov)
P1, N=36, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
4 months ago
Enrollment closed • Combination therapy • Metastases
|
ezabenlimab (BI 754091) • BI 770371
6ms
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
P1, N=13, Recruiting, Boehringer Ingelheim | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Jul 2024 --> Jan 2025
6 months ago
Trial completion date • Trial primary completion date • Metastases
|
SIRPA (Signal Regulatory Protein Alpha)
|
ezabenlimab (BI 754091) • BI 765063 • BI 770371
7ms
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated (clinicaltrials.gov)
P1, N=42, Recruiting, Boehringer Ingelheim | Trial completion date: Nov 2025 --> Jan 2025 | Trial primary completion date: Mar 2025 --> Jul 2024
7 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ezabenlimab (BI 754091) • BI 770371
1year
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab (clinicaltrials.gov)
P1, N=12, Recruiting, Boehringer Ingelheim | N=22 --> 12 | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Apr 2024
1 year ago
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
SIRPA (Signal Regulatory Protein Alpha)
|
ezabenlimab (BI 754091) • BI 765063 • BI 770371
over1year
Open-label, phase I, dose escalation/expansion trial of the anti-SIRPα monoclonal antibody BI 770371 in patients with advanced solid tumours, alone or in combination with the anti-PD-1 monoclonal antibody ezabenlimab (ESMO 2023)
Conclusions BI 770371 showed manageable toxicity alone and in combination with ezabenlimab. The trial is ongoing.
over 1 year ago
Clinical • Combination therapy • Metastases
|
SIRPA (Signal Regulatory Protein Alpha)
|
ezabenlimab (BI 754091) • BI 770371
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login